APO Research
Talk to an analyst

APO RESEARCH · REPORT

Biologics Clinical Manufacturing CDMO Service

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Biologics Clinical Manufacturing CDMO Service Market Outlook and Growth Opportunities 2026

11 April 2026Not stated

Choose your research edition.

Industry ResearchBiologics Clinical Manufacturing CDMO Service Industry Research Report 2026130 pages · $2,950 USDIndustry Growth & TrendsGlobal Biologics Clinical Manufacturing CDMO Service Industry Growth and Trends Forecast to 2032114 pages · $3,450 USDMarket StructureGlobal Biologics Clinical Manufacturing CDMO Service Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Biologics Clinical Manufacturing CDMO Service Market Outlook and Growth Opportunities 2026$4,250 USDMarket Analysis & ForecastGlobal Biologics Clinical Manufacturing CDMO Service Market Analysis and Forecast 2026-2032241 pages · $4,950 USD

Market perspective

The global Biologics Clinical Manufacturing CDMO Service market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Biologics Clinical Manufacturing CDMO Service is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Biologics Clinical Manufacturing CDMO Service is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Biologics Clinical Manufacturing CDMO Service is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Biologics Clinical Manufacturing CDMO Service market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Biologics Clinical Manufacturing CDMO Service market include Thermo Fisher Scientific, Lonza, Intertek, Charles River Laboratories, Bio-Rad, Element, ProPharma, Ascendia and Minaris Regenerative Medicine, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Biologics Clinical Manufacturing CDMO Service market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Biologics Clinical Manufacturing CDMO Service and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Biologics Clinical Manufacturing CDMO Service revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Biologics Clinical Manufacturing CDMO Service market.

Biologics Clinical Manufacturing CDMO Service Segment by Company

Thermo Fisher Scientific

Lonza

Intertek

Charles River Laboratories

Bio-Rad

Element

ProPharma

Ascendia

Minaris Regenerative Medicine

TriLink BioTechnologies

Oakwood Labs

PiramalPharma Solutions

Boehringer-Ingelheim

Wuxi Apptec

Pharmaron Beijing

Asymchem Laboratories (Tianjin)

Porton

SEQENS

Biologics Clinical Manufacturing CDMO Service Segment by Type

Traditional API CDMO

Highly Potent API CDMO

Biologics Clinical Manufacturing CDMO Service Segment by Application

Big Pharmaceutical Companies

Small and Medium Pharmaceutical Companies

Biologics Clinical Manufacturing CDMO Service Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Biologics Clinical Manufacturing CDMO Service status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Biologics Clinical Manufacturing CDMO Service key companies, revenue, market share, and recent developments.

3. To split the Biologics Clinical Manufacturing CDMO Service breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Biologics Clinical Manufacturing CDMO Service market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Biologics Clinical Manufacturing CDMO Service significant trends, drivers, influence factors in global and regions.

6. To analyze Biologics Clinical Manufacturing CDMO Service competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biologics Clinical Manufacturing CDMO Service market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Biologics Clinical Manufacturing CDMO Service and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biologics Clinical Manufacturing CDMO Service.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Biologics Clinical Manufacturing CDMO Service industry.

Chapter 3: Detailed analysis of Biologics Clinical Manufacturing CDMO Service company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Biologics Clinical Manufacturing CDMO Service in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Biologics Clinical Manufacturing CDMO Service in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Biologics Clinical Manufacturing CDMO Service Industry Trends Table 2. Biologics Clinical Manufacturing CDMO Service Industry Drivers Table 3. Biologics Clinical Manufacturing CDMO Service Industry Opportunities and Challenges Table 4. Biologics Clinical Manufacturing CDMO Service Industry Restraints Table 5. Global Biologics Clinical Manufacturing CDMO Service Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Biologics Clinical Manufacturing CDMO Service Revenue Share by Company (2021-2026) Table 7. Global Biologics Clinical Manufacturing CDMO Service Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Biologics Clinical Manufacturing CDMO Service Key Company Manufacturing Base & Headquarters Table 9. Global Biologics Clinical Manufacturing CDMO Service Company, Product Type & Application Table 10. Global Biologics Clinical Manufacturing CDMO Service Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Biologics Clinical Manufacturing CDMO Service by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Traditional API CDMO Table 15. Significant Companies of Highly Potent API CDMO Table 16. Global Biologics Clinical Manufacturing CDMO Service Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Biologics Clinical Manufacturing CDMO Service Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Biologics Clinical Manufacturing CDMO Service Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Biologics Clinical Manufacturing CDMO Service Sales Value Share by Type (2021-2026) Table 20. Global Biologics Clinical Manufacturing CDMO Service Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Big Pharmaceutical Companies Table 22. Significant Companies of Small and Medium Pharmaceutical Companies Table 23. Global Biologics Clinical Manufacturing CDMO Service Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 24. Global Biologics Clinical Manufacturing CDMO Service Sales Value by Application (2021-2026) & (US$ Million) Table 25. Global Biologics Clinical Manufacturing CDMO Service Sales Value by Application (2027-2032) & (US$ Million) Table 26. Global Biologics Clinical Manufacturing CDMO Service Sales Value Share by Application (2021-2026) Table 27. Global Biologics Clinical Manufacturing CDMO Service Sales Value Share by Application (2027-2032) Table 28. Global Biologics Clinical Manufacturing CDMO Service Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Biologics Clinical Manufacturing CDMO Service Sales Value by Region (2021-2026) & (US$ Million) Table 30. Global Biologics Clinical Manufacturing CDMO Service Sales Value Share by Region (2021-2026) Table 31. Global Biologics Clinical Manufacturing CDMO Service Sales Value by Region (2027-2032) & (US$ Million) Table 32. Global Biologics Clinical Manufacturing CDMO Service Sales Value Share by Region (2027-2032) Table 33. Global Biologics Clinical Manufacturing CDMO Service Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Biologics Clinical Manufacturing CDMO Service Sales Value by Country (2021-2026) & (US$ Million) Table 35. Global Biologics Clinical Manufacturing CDMO Service Sales Value Market Share by Country (2021-2026) Table 36. Global Biologics Clinical Manufacturing CDMO Service Sales Value by Country (2027-2032) & (US$ Million) Table 37. Global Biologics Clinical Manufacturing CDMO Service Sales Value Market Share by Country (2027-2032) Table 38. Thermo Fisher Scientific Company Information Table 39. Thermo Fisher Scientific Business Overview Table 40. Thermo Fisher Scientific Biologics Clinical Manufacturing CDMO Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 41. Thermo Fisher Scientific Biologics Clinical Manufacturing CDMO Service Product Portfolio Table 42. Thermo Fisher Scientific Recent Development Table 43. Lonza Company Information Table 44. Lonza Business Overview Table 45. Lonza Biologics Clinical Manufacturing CDMO Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 46. Lonza Biologics Clinical Manufacturing CDMO Service Product Portfolio Table 47. Lonza Recent Development Table 48. Intertek Company Information Table 49. Intertek Business Overview Table 50. Intertek Biologics Clinical Manufacturing CDMO Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 51. Intertek Biologics Clinical Manufacturing CDMO Service Product Portfolio Table 52. Intertek Recent Development Table 53. Charles River Laboratories Company Information Table 54. Charles River Laboratories Business Overview Table 55. Charles River Laboratories Biologics Clinical Manufacturing CDMO Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 56. Charles River Laboratories Biologics Clinical Manufacturing CDMO Service Product Portfolio Table 57. Charles River Laboratories Recent Development Table 58. Bio-Rad Company Information Table 59. Bio-Rad Business Overview Table 60. Bio-Rad Biologics Clinical Manufacturing CDMO Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 61. Bio-Rad Biologics Clinical Manufacturing CDMO Service Product Portfolio Table 62. Bio-Rad Recent Development Table 63. Element Company Information Table 64. Element Business Overview Table 65. Element Biologics Clinical Manufacturing CDMO Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Element Biologics Clinical Manufacturing CDMO Service Product Portfolio Table 67. Element Recent Development Table 68. ProPharma Company Information Table 69. ProPharma Business Overview Table 70. ProPharma Biologics Clinical Manufacturing CDMO Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. ProPharma Biologics Clinical Manufacturing CDMO Service Product Portfolio Table 72. ProPharma Recent Development Table 73. Ascendia Company Information Table 74. Ascendia Business Overview Table 75. Ascendia Biologics Clinical Manufacturing CDMO Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Ascendia Biologics Clinical Manufacturing CDMO Service Product Portfolio Table 77. Ascendia Recent Development Table 78. Minaris Regenerative Medicine Company Information Table 79. Minaris Regenerative Medicine Business Overview Table 80. Minaris Regenerative Medicine Biologics Clinical Manufacturing CDMO Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Minaris Regenerative Medicine Biologics Clinical Manufacturing CDMO Service Product Portfolio Table 82. Minaris Regenerative Medicine Recent Development Table 83. TriLink BioTechnologies Company Information Table 84. TriLink BioTechnologies Business Overview Table 85. TriLink BioTechnologies Biologics Clinical Manufacturing CDMO Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. TriLink BioTechnologies Biologics Clinical Manufacturing CDMO Service Product Portfolio Table 87. TriLink BioTechnologies Recent Development Table 88. Oakwood Labs Company Information Table 89. Oakwood Labs Business Overview Table 90. Oakwood Labs Biologics Clinical Manufacturing CDMO Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 91. Oakwood Labs Biologics Clinical Manufacturing CDMO Service Product Portfolio Table 92. Oakwood Labs Recent Development Table 93. PiramalPharma Solutions Company Information Table 94. PiramalPharma Solutions Business Overview Table 95. PiramalPharma Solutions Biologics Clinical Manufacturing CDMO Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 96. PiramalPharma Solutions Biologics Clinical Manufacturing CDMO Service Product Portfolio Table 97. PiramalPharma Solutions Recent Development Table 98. Boehringer-Ingelheim Company Information Table 99. Boehringer-Ingelheim Business Overview Table 100. Boehringer-Ingelheim Biologics Clinical Manufacturing CDMO Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 101. Boehringer-Ingelheim Biologics Clinical Manufacturing CDMO Service Product Portfolio Table 102. Boehringer-Ingelheim Recent Development Table 103. Wuxi Apptec Company Information Table 104. Wuxi Apptec Business Overview Table 105. Wuxi Apptec Biologics Clinical Manufacturing CDMO Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 106. Wuxi Apptec Biologics Clinical Manufacturing CDMO Service Product Portfolio Table 107. Wuxi Apptec Recent Development Table 108. Pharmaron Beijing Company Information Table 109. Pharmaron Beijing Business Overview Table 110. Pharmaron Beijing Biologics Clinical Manufacturing CDMO Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 111. Pharmaron Beijing Biologics Clinical Manufacturing CDMO Service Product Portfolio Table 112. Pharmaron Beijing Recent Development Table 113. Asymchem Laboratories (Tianjin) Company Information Table 114. Asymchem Laboratories (Tianjin) Business Overview Table 115. Asymchem Laboratories (Tianjin) Biologics Clinical Manufacturing CDMO Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 116. Asymchem Laboratories (Tianjin) Biologics Clinical Manufacturing CDMO Service Product Portfolio Table 117. Asymchem Laboratories (Tianjin) Recent Development Table 118. Porton Company Information Table 119. Porton Business Overview Table 120. Porton Biologics Clinical Manufacturing CDMO Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 121. Porton Biologics Clinical Manufacturing CDMO Service Product Portfolio Table 122. Porton Recent Development Table 123. SEQENS Company Information Table 124. SEQENS Business Overview Table 125. SEQENS Biologics Clinical Manufacturing CDMO Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 126. SEQENS Biologics Clinical Manufacturing CDMO Service Product Portfolio Table 127. SEQENS Recent Development Table 128. Research Programs/Design for This Report Table 129. Authors List of This Report Table 130. Secondary Sources Table 131. Primary Sources List of Figures Figure 1. Biologics Clinical Manufacturing CDMO Service Product Image Figure 2. Global Biologics Clinical Manufacturing CDMO Service Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Biologics Clinical Manufacturing CDMO Service Market Size (2021-2032) & (US$ Million) Figure 4. Global Biologics Clinical Manufacturing CDMO Service Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Traditional API CDMO Image Figure 8. Highly Potent API CDMO Image Figure 9. Global Biologics Clinical Manufacturing CDMO Service Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Biologics Clinical Manufacturing CDMO Service Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Biologics Clinical Manufacturing CDMO Service Sales Value Share by Type (2021-2032) Figure 12. Big Pharmaceutical Companies Image Figure 13. Small and Medium Pharmaceutical Companies Image Figure 14. Global Biologics Clinical Manufacturing CDMO Service Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Biologics Clinical Manufacturing CDMO Service Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Biologics Clinical Manufacturing CDMO Service Sales Value Share by Application (2021-2032) Figure 17. Global Biologics Clinical Manufacturing CDMO Service Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 18. Global Biologics Clinical Manufacturing CDMO Service Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 19. North America Biologics Clinical Manufacturing CDMO Service Sales Value (2021-2032) & (US$ Million) Figure 20. North America Biologics Clinical Manufacturing CDMO Service Sales Value Share by Country (%), 2025 VS 2032 Figure 21. Europe Biologics Clinical Manufacturing CDMO Service Sales Value (2021-2032) & (US$ Million) Figure 22. Europe Biologics Clinical Manufacturing CDMO Service Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Asia-Pacific Biologics Clinical Manufacturing CDMO Service Sales Value (2021-2032) & (US$ Million) Figure 24. Asia-Pacific Biologics Clinical Manufacturing CDMO Service Sales Value Share by Country (%), 2025 VS 2032 Figure 25. South America Biologics Clinical Manufacturing CDMO Service Sales Value (2021-2032) & (US$ Million) Figure 26. South America Biologics Clinical Manufacturing CDMO Service Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Middle East & Africa Biologics Clinical Manufacturing CDMO Service Sales Value (2021-2032) & (US$ Million) Figure 28. Middle East & Africa Biologics Clinical Manufacturing CDMO Service Sales Value Share by Country (%), 2025 VS 2032 Figure 29. USA Biologics Clinical Manufacturing CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 30. USA Biologics Clinical Manufacturing CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 31. USA Biologics Clinical Manufacturing CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 32. Canada Biologics Clinical Manufacturing CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. Canada Biologics Clinical Manufacturing CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. Canada Biologics Clinical Manufacturing CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Mexico Biologics Clinical Manufacturing CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Mexico Biologics Clinical Manufacturing CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Mexico Biologics Clinical Manufacturing CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Germany Biologics Clinical Manufacturing CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Germany Biologics Clinical Manufacturing CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Germany Biologics Clinical Manufacturing CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. France Biologics Clinical Manufacturing CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. France Biologics Clinical Manufacturing CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. France Biologics Clinical Manufacturing CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. U.K. Biologics Clinical Manufacturing CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. U.K. Biologics Clinical Manufacturing CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. U.K. Biologics Clinical Manufacturing CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Italy Biologics Clinical Manufacturing CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Italy Biologics Clinical Manufacturing CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Italy Biologics Clinical Manufacturing CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Spain Biologics Clinical Manufacturing CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Spain Biologics Clinical Manufacturing CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Spain Biologics Clinical Manufacturing CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Russia Biologics Clinical Manufacturing CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Russia Biologics Clinical Manufacturing CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Russia Biologics Clinical Manufacturing CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Netherlands Biologics Clinical Manufacturing CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Netherlands Biologics Clinical Manufacturing CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Netherlands Biologics Clinical Manufacturing CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Nordic Countries Biologics Clinical Manufacturing CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Nordic Countries Biologics Clinical Manufacturing CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Nordic Countries Biologics Clinical Manufacturing CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. China Biologics Clinical Manufacturing CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. China Biologics Clinical Manufacturing CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. China Biologics Clinical Manufacturing CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Japan Biologics Clinical Manufacturing CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Japan Biologics Clinical Manufacturing CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Japan Biologics Clinical Manufacturing CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. South Korea Biologics Clinical Manufacturing CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. South Korea Biologics Clinical Manufacturing CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. South Korea Biologics Clinical Manufacturing CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. India Biologics Clinical Manufacturing CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. India Biologics Clinical Manufacturing CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. India Biologics Clinical Manufacturing CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. Australia Biologics Clinical Manufacturing CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. Australia Biologics Clinical Manufacturing CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. Australia Biologics Clinical Manufacturing CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Southeast Asia Biologics Clinical Manufacturing CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Southeast Asia Biologics Clinical Manufacturing CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Southeast Asia Biologics Clinical Manufacturing CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Brazil Biologics Clinical Manufacturing CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Brazil Biologics Clinical Manufacturing CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Brazil Biologics Clinical Manufacturing CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Argentina Biologics Clinical Manufacturing CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Argentina Biologics Clinical Manufacturing CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Argentina Biologics Clinical Manufacturing CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Chile Biologics Clinical Manufacturing CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Chile Biologics Clinical Manufacturing CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Chile Biologics Clinical Manufacturing CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Colombia Biologics Clinical Manufacturing CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Colombia Biologics Clinical Manufacturing CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Colombia Biologics Clinical Manufacturing CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Peru Biologics Clinical Manufacturing CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Peru Biologics Clinical Manufacturing CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Peru Biologics Clinical Manufacturing CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Saudi Arabia Biologics Clinical Manufacturing CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Saudi Arabia Biologics Clinical Manufacturing CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Biologics Clinical Manufacturing CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Israel Biologics Clinical Manufacturing CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Israel Biologics Clinical Manufacturing CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Israel Biologics Clinical Manufacturing CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. UAE Biologics Clinical Manufacturing CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. UAE Biologics Clinical Manufacturing CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. UAE Biologics Clinical Manufacturing CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Turkey Biologics Clinical Manufacturing CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Turkey Biologics Clinical Manufacturing CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Turkey Biologics Clinical Manufacturing CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Iran Biologics Clinical Manufacturing CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Iran Biologics Clinical Manufacturing CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Iran Biologics Clinical Manufacturing CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Egypt Biologics Clinical Manufacturing CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Egypt Biologics Clinical Manufacturing CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Egypt Biologics Clinical Manufacturing CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Years Considered Figure 114. Research Process Figure 115. Key Executives Interviewed

Scope & coverage.

Types
  • Traditional API CDMO
  • Highly Potent API CDMO
Applications
  • Big Pharmaceutical Companies
  • Small and Medium Pharmaceutical Companies
Companies covered
  • Thermo Fisher Scientific
  • Lonza
  • Intertek
  • Charles River Laboratories
  • Bio-Rad
  • Element
  • ProPharma
  • Ascendia
  • Minaris Regenerative Medicine
  • TriLink BioTechnologies
  • Oakwood Labs
  • PiramalPharma Solutions
  • Boehringer-Ingelheim
  • Wuxi Apptec
  • Pharmaron Beijing
  • Asymchem Laboratories (Tianjin)
  • Porton
  • SEQENS

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Biologics Clinical Manufacturing CDMO Service Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Biologics Clinical Manufacturing CDMO Service Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Biologics Clinical Manufacturing CDMO Service Market Dynamics
  1. 2.1 Biologics Clinical Manufacturing CDMO Service Industry Trends
  2. 2.2 Biologics Clinical Manufacturing CDMO Service Industry Drivers
  3. 2.3 Biologics Clinical Manufacturing CDMO Service Industry Opportunities and Challenges
  4. 2.4 Biologics Clinical Manufacturing CDMO Service Industry Restraints
3 Biologics Clinical Manufacturing CDMO Service Market by Company
  1. 3.1 Global Biologics Clinical Manufacturing CDMO Service Company Revenue Ranking in 2025
  2. 3.2 Global Biologics Clinical Manufacturing CDMO Service Revenue by Company (2021-2026)
  3. 3.3 Global Biologics Clinical Manufacturing CDMO Service Company Ranking (2024-2026)
  4. 3.4 Global Biologics Clinical Manufacturing CDMO Service Company Manufacturing Base and Headquarters
  5. 3.5 Global Biologics Clinical Manufacturing CDMO Service Company Product Type and Application
  6. 3.6 Global Biologics Clinical Manufacturing CDMO Service Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Biologics Clinical Manufacturing CDMO Service Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Biologics Clinical Manufacturing CDMO Service Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Biologics Clinical Manufacturing CDMO Service Market by Type
  1. 4.1 Biologics Clinical Manufacturing CDMO Service Type Introduction
  2. 4.1.1 Traditional API CDMO
  3. 4.1.2 Highly Potent API CDMO
  4. 4.2 Global Biologics Clinical Manufacturing CDMO Service Sales Value by Type
  5. 4.2.1 Global Biologics Clinical Manufacturing CDMO Service Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Biologics Clinical Manufacturing CDMO Service Sales Value by Type (2021-2032)
  7. 4.2.3 Global Biologics Clinical Manufacturing CDMO Service Sales Value Share by Type (2021-2032)
5 Biologics Clinical Manufacturing CDMO Service Market by Application
  1. 5.1 Biologics Clinical Manufacturing CDMO Service Application Introduction
  2. 5.1.1 Big Pharmaceutical Companies
  3. 5.1.2 Small and Medium Pharmaceutical Companies
  4. 5.2 Global Biologics Clinical Manufacturing CDMO Service Sales Value by Application
  5. 5.2.1 Global Biologics Clinical Manufacturing CDMO Service Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Biologics Clinical Manufacturing CDMO Service Sales Value by Application (2021-2032)
  7. 5.2.3 Global Biologics Clinical Manufacturing CDMO Service Sales Value Share by Application (2021-2032)
6 Biologics Clinical Manufacturing CDMO Service Regional Value Analysis
  1. 6.1 Global Biologics Clinical Manufacturing CDMO Service Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Biologics Clinical Manufacturing CDMO Service Sales Value by Region (2021-2032)
  3. 6.2.1 Global Biologics Clinical Manufacturing CDMO Service Sales Value by Region: 2021-2026
  4. 6.2.2 Global Biologics Clinical Manufacturing CDMO Service Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Biologics Clinical Manufacturing CDMO Service Sales Value (2021-2032)
  7. 6.3.2 North America Biologics Clinical Manufacturing CDMO Service Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Biologics Clinical Manufacturing CDMO Service Sales Value (2021-2032)
  10. 6.4.2 Europe Biologics Clinical Manufacturing CDMO Service Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Biologics Clinical Manufacturing CDMO Service Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Biologics Clinical Manufacturing CDMO Service Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Biologics Clinical Manufacturing CDMO Service Sales Value (2021-2032)
  16. 6.6.2 South America Biologics Clinical Manufacturing CDMO Service Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Biologics Clinical Manufacturing CDMO Service Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Biologics Clinical Manufacturing CDMO Service Sales Value Share by Country, 2025 VS 2032
7 Biologics Clinical Manufacturing CDMO Service Country-level Value Analysis
  1. 7.1 Global Biologics Clinical Manufacturing CDMO Service Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Biologics Clinical Manufacturing CDMO Service Sales Value by Country (2021-2032)
  3. 7.2.1 Global Biologics Clinical Manufacturing CDMO Service Sales Value by Country (2021-2026)
  4. 7.2.2 Global Biologics Clinical Manufacturing CDMO Service Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Biologics Clinical Manufacturing CDMO Service Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Biologics Clinical Manufacturing CDMO Service Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Biologics Clinical Manufacturing CDMO Service Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Biologics Clinical Manufacturing CDMO Service Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Biologics Clinical Manufacturing CDMO Service Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Biologics Clinical Manufacturing CDMO Service Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Biologics Clinical Manufacturing CDMO Service Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Biologics Clinical Manufacturing CDMO Service Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Biologics Clinical Manufacturing CDMO Service Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Biologics Clinical Manufacturing CDMO Service Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Biologics Clinical Manufacturing CDMO Service Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Biologics Clinical Manufacturing CDMO Service Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Biologics Clinical Manufacturing CDMO Service Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Biologics Clinical Manufacturing CDMO Service Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Biologics Clinical Manufacturing CDMO Service Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Biologics Clinical Manufacturing CDMO Service Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Biologics Clinical Manufacturing CDMO Service Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Biologics Clinical Manufacturing CDMO Service Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Biologics Clinical Manufacturing CDMO Service Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Biologics Clinical Manufacturing CDMO Service Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Biologics Clinical Manufacturing CDMO Service Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Biologics Clinical Manufacturing CDMO Service Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Biologics Clinical Manufacturing CDMO Service Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Biologics Clinical Manufacturing CDMO Service Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Biologics Clinical Manufacturing CDMO Service Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Biologics Clinical Manufacturing CDMO Service Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Biologics Clinical Manufacturing CDMO Service Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Biologics Clinical Manufacturing CDMO Service Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Biologics Clinical Manufacturing CDMO Service Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Biologics Clinical Manufacturing CDMO Service Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Biologics Clinical Manufacturing CDMO Service Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Biologics Clinical Manufacturing CDMO Service Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Biologics Clinical Manufacturing CDMO Service Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Biologics Clinical Manufacturing CDMO Service Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Biologics Clinical Manufacturing CDMO Service Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Biologics Clinical Manufacturing CDMO Service Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Biologics Clinical Manufacturing CDMO Service Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Biologics Clinical Manufacturing CDMO Service Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Biologics Clinical Manufacturing CDMO Service Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Biologics Clinical Manufacturing CDMO Service Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Biologics Clinical Manufacturing CDMO Service Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Biologics Clinical Manufacturing CDMO Service Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Biologics Clinical Manufacturing CDMO Service Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Biologics Clinical Manufacturing CDMO Service Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Biologics Clinical Manufacturing CDMO Service Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Biologics Clinical Manufacturing CDMO Service Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Biologics Clinical Manufacturing CDMO Service Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Biologics Clinical Manufacturing CDMO Service Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Biologics Clinical Manufacturing CDMO Service Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Biologics Clinical Manufacturing CDMO Service Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Biologics Clinical Manufacturing CDMO Service Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Biologics Clinical Manufacturing CDMO Service Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Biologics Clinical Manufacturing CDMO Service Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Biologics Clinical Manufacturing CDMO Service Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Biologics Clinical Manufacturing CDMO Service Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Biologics Clinical Manufacturing CDMO Service Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Biologics Clinical Manufacturing CDMO Service Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Biologics Clinical Manufacturing CDMO Service Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Biologics Clinical Manufacturing CDMO Service Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Biologics Clinical Manufacturing CDMO Service Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Biologics Clinical Manufacturing CDMO Service Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Biologics Clinical Manufacturing CDMO Service Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Biologics Clinical Manufacturing CDMO Service Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Biologics Clinical Manufacturing CDMO Service Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Biologics Clinical Manufacturing CDMO Service Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Biologics Clinical Manufacturing CDMO Service Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Biologics Clinical Manufacturing CDMO Service Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Biologics Clinical Manufacturing CDMO Service Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Biologics Clinical Manufacturing CDMO Service Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Biologics Clinical Manufacturing CDMO Service Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Biologics Clinical Manufacturing CDMO Service Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Biologics Clinical Manufacturing CDMO Service Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Biologics Clinical Manufacturing CDMO Service Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Biologics Clinical Manufacturing CDMO Service Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Biologics Clinical Manufacturing CDMO Service Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Biologics Clinical Manufacturing CDMO Service Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Biologics Clinical Manufacturing CDMO Service Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Biologics Clinical Manufacturing CDMO Service Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Biologics Clinical Manufacturing CDMO Service Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Biologics Clinical Manufacturing CDMO Service Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Biologics Clinical Manufacturing CDMO Service Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Biologics Clinical Manufacturing CDMO Service Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Biologics Clinical Manufacturing CDMO Service Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Biologics Clinical Manufacturing CDMO Service Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Thermo Fisher Scientific
  2. 8.1.1 Thermo Fisher Scientific Company Information
  3. 8.1.2 Thermo Fisher Scientific Business Overview
  4. 8.1.3 Thermo Fisher Scientific Biologics Clinical Manufacturing CDMO Service Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Thermo Fisher Scientific Biologics Clinical Manufacturing CDMO Service Product Portfolio
  6. 8.1.5 Thermo Fisher Scientific Recent Developments
  7. 8.2 Lonza
  8. 8.2.1 Lonza Company Information
  9. 8.2.2 Lonza Business Overview
  10. 8.2.3 Lonza Biologics Clinical Manufacturing CDMO Service Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Lonza Biologics Clinical Manufacturing CDMO Service Product Portfolio
  12. 8.2.5 Lonza Recent Developments
  13. 8.3 Intertek
  14. 8.3.1 Intertek Company Information
  15. 8.3.2 Intertek Business Overview
  16. 8.3.3 Intertek Biologics Clinical Manufacturing CDMO Service Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Intertek Biologics Clinical Manufacturing CDMO Service Product Portfolio
  18. 8.3.5 Intertek Recent Developments
  19. 8.4 Charles River Laboratories
  20. 8.4.1 Charles River Laboratories Company Information
  21. 8.4.2 Charles River Laboratories Business Overview
  22. 8.4.3 Charles River Laboratories Biologics Clinical Manufacturing CDMO Service Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Charles River Laboratories Biologics Clinical Manufacturing CDMO Service Product Portfolio
  24. 8.4.5 Charles River Laboratories Recent Developments
  25. 8.5 Bio-Rad
  26. 8.5.1 Bio-Rad Company Information
  27. 8.5.2 Bio-Rad Business Overview
  28. 8.5.3 Bio-Rad Biologics Clinical Manufacturing CDMO Service Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Bio-Rad Biologics Clinical Manufacturing CDMO Service Product Portfolio
  30. 8.5.5 Bio-Rad Recent Developments
  31. 8.6 Element
  32. 8.6.1 Element Company Information
  33. 8.6.2 Element Business Overview
  34. 8.6.3 Element Biologics Clinical Manufacturing CDMO Service Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Element Biologics Clinical Manufacturing CDMO Service Product Portfolio
  36. 8.6.5 Element Recent Developments
  37. 8.7 ProPharma
  38. 8.7.1 ProPharma Company Information
  39. 8.7.2 ProPharma Business Overview
  40. 8.7.3 ProPharma Biologics Clinical Manufacturing CDMO Service Revenue and Gross Margin (2021-2026)
  41. 8.7.4 ProPharma Biologics Clinical Manufacturing CDMO Service Product Portfolio
  42. 8.7.5 ProPharma Recent Developments
  43. 8.8 Ascendia
  44. 8.8.1 Ascendia Company Information
  45. 8.8.2 Ascendia Business Overview
  46. 8.8.3 Ascendia Biologics Clinical Manufacturing CDMO Service Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Ascendia Biologics Clinical Manufacturing CDMO Service Product Portfolio
  48. 8.8.5 Ascendia Recent Developments
  49. 8.9 Minaris Regenerative Medicine
  50. 8.9.1 Minaris Regenerative Medicine Company Information
  51. 8.9.2 Minaris Regenerative Medicine Business Overview
  52. 8.9.3 Minaris Regenerative Medicine Biologics Clinical Manufacturing CDMO Service Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Minaris Regenerative Medicine Biologics Clinical Manufacturing CDMO Service Product Portfolio
  54. 8.9.5 Minaris Regenerative Medicine Recent Developments
  55. 8.10 TriLink BioTechnologies
  56. 8.10.1 TriLink BioTechnologies Company Information
  57. 8.10.2 TriLink BioTechnologies Business Overview
  58. 8.10.3 TriLink BioTechnologies Biologics Clinical Manufacturing CDMO Service Revenue and Gross Margin (2021-2026)
  59. 8.10.4 TriLink BioTechnologies Biologics Clinical Manufacturing CDMO Service Product Portfolio
  60. 8.10.5 TriLink BioTechnologies Recent Developments
  61. 8.11 Oakwood Labs
  62. 8.11.1 Oakwood Labs Company Information
  63. 8.11.2 Oakwood Labs Business Overview
  64. 8.11.3 Oakwood Labs Biologics Clinical Manufacturing CDMO Service Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Oakwood Labs Biologics Clinical Manufacturing CDMO Service Product Portfolio
  66. 8.11.5 Oakwood Labs Recent Developments
  67. 8.12 PiramalPharma Solutions
  68. 8.12.1 PiramalPharma Solutions Company Information
  69. 8.12.2 PiramalPharma Solutions Business Overview
  70. 8.12.3 PiramalPharma Solutions Biologics Clinical Manufacturing CDMO Service Revenue and Gross Margin (2021-2026)
  71. 8.12.4 PiramalPharma Solutions Biologics Clinical Manufacturing CDMO Service Product Portfolio
  72. 8.12.5 PiramalPharma Solutions Recent Developments
  73. 8.13 Boehringer-Ingelheim
  74. 8.13.1 Boehringer-Ingelheim Company Information
  75. 8.13.2 Boehringer-Ingelheim Business Overview
  76. 8.13.3 Boehringer-Ingelheim Biologics Clinical Manufacturing CDMO Service Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Boehringer-Ingelheim Biologics Clinical Manufacturing CDMO Service Product Portfolio
  78. 8.13.5 Boehringer-Ingelheim Recent Developments
  79. 8.14 Wuxi Apptec
  80. 8.14.1 Wuxi Apptec Company Information
  81. 8.14.2 Wuxi Apptec Business Overview
  82. 8.14.3 Wuxi Apptec Biologics Clinical Manufacturing CDMO Service Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Wuxi Apptec Biologics Clinical Manufacturing CDMO Service Product Portfolio
  84. 8.14.5 Wuxi Apptec Recent Developments
  85. 8.15 Pharmaron Beijing
  86. 8.15.1 Pharmaron Beijing Company Information
  87. 8.15.2 Pharmaron Beijing Business Overview
  88. 8.15.3 Pharmaron Beijing Biologics Clinical Manufacturing CDMO Service Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Pharmaron Beijing Biologics Clinical Manufacturing CDMO Service Product Portfolio
  90. 8.15.5 Pharmaron Beijing Recent Developments
  91. 8.16 Asymchem Laboratories (Tianjin)
  92. 8.16.1 Asymchem Laboratories (Tianjin) Company Information
  93. 8.16.2 Asymchem Laboratories (Tianjin) Business Overview
  94. 8.16.3 Asymchem Laboratories (Tianjin) Biologics Clinical Manufacturing CDMO Service Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Asymchem Laboratories (Tianjin) Biologics Clinical Manufacturing CDMO Service Product Portfolio
  96. 8.16.5 Asymchem Laboratories (Tianjin) Recent Developments
  97. 8.17 Porton
  98. 8.17.1 Porton Company Information
  99. 8.17.2 Porton Business Overview
  100. 8.17.3 Porton Biologics Clinical Manufacturing CDMO Service Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Porton Biologics Clinical Manufacturing CDMO Service Product Portfolio
  102. 8.17.5 Porton Recent Developments
  103. 8.18 SEQENS
  104. 8.18.1 SEQENS Company Information
  105. 8.18.2 SEQENS Business Overview
  106. 8.18.3 SEQENS Biologics Clinical Manufacturing CDMO Service Revenue and Gross Margin (2021-2026)
  107. 8.18.4 SEQENS Biologics Clinical Manufacturing CDMO Service Product Portfolio
  108. 8.18.5 SEQENS Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst